) The activities of the Clinical Investigations Shared Resource are centered around the Patient Referral Office. This resource is offered to member-investigators of the San Antonio Cancer Institute to support appropriate referral to and rapid completion of peer reviewed, funded clinical research projects and investigator-initiated pilot studies. The Patient Referral Office is the primary venue for patient access to cancer center clinical trials. The Patient Referral Coordinator accepts telephone inquiries from physicians, patients and others about the availability of clinical trials. Contacts by mail are also addressed through phone calls from this office. The Patient Referral Coordinator can assess preliminary patient eligibility by phone, assemble clinical data for review, and arrange an evaluation by a SACI physician-investigator. Since January 1, 1997, this office has accepted 1,255 telephone calls about access to clinical trials or cancer. These calls may be brief, single contacts or many initiate several hours or conversation and multiple follow-up calls between the coordinator and the referring oncologist, patient, protocol investigators and cancer center personnel. The Patient Referral Coordinator is equipped to provide callers with up- to-date eligibility and treatment about all therapeutic clinical research studies conducted at this cancer center, including all cooperative group studies, NCI Phase I Cooperative Agreement studies, investigator-initiated institutional pilot studies, and pharmaceutical company-sponsored studies conducted under the SACI Experimental Therapeutics Program, as well as the NSABP Breast Cancer Prevention Trial, the Intergroup Prostate Cancer Prevention Trial, and referrals for evaluation in the SACI Cancer Prevention and Risk Assessment Clinic related to studies conduced by the SACI Cancer Prevention and Health Promotion and Breast Cancer Programs. The Patient Referral Office has become an essential and central component of our cancer center's interactions with the community and with other cancer treatment facilities. The office provides an efficient mechanism for assuring the highest likelihood of matching a clinical trial with a patient's treatment needs. It is noteworthy that the Patient Referral Coordinator's special value to the clinical investigations programs of the SACI is her level of expertise in obtaining in-depth information from callers about their treatment needs, the caller's potential for participation in a SACI clinical trial, and developing realistic plans for the caller's further evaluation in our setting or that of another cancer center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA054174-09
Application #
6203203
Study Section
Project Start
1999-08-01
Project End
2000-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
9
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Ctrc Research Foundation
Department
Type
DUNS #
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Chalela, Patricia; Muñoz, Edgar; Gallion, Kipling J et al. (2018) Empowering Latina breast cancer patients to make informed decisions about clinical trials: a pilot study. Transl Behav Med 8:439-449
Chalela, P; Munoz, E; Inupakutika, D et al. (2018) Improving adherence to endocrine hormonal therapy among breast cancer patients: Study protocol for a randomized controlled trial. Contemp Clin Trials Commun 12:109-115
Weiner, Marc; Gelfond, Jon; Johnson-Pais, Teresa L et al. (2018) Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis. Antimicrob Agents Chemother 62:
Liu, Jinyou; Sareddy, Gangadhara R; Zhou, Mei et al. (2018) Differential Effects of Estrogen Receptor ? Isoforms on Glioblastoma Progression. Cancer Res 78:3176-3189
Chakravarthy, Divya; Muñoz, Amanda R; Su, Angel et al. (2018) Palmatine suppresses glutamine-mediated interaction between pancreatic cancer and stellate cells through simultaneous inhibition of survivin and COL1A1. Cancer Lett 419:103-115
Van Skike, Candice E; Jahrling, Jordan B; Olson, Angela B et al. (2018) Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment. Am J Physiol Heart Circ Physiol 314:H693-H703
Cooney, Jeffrey D; Lin, An-Ping; Jiang, Daifeng et al. (2018) Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3K? in Mature B-cell Malignancies. Clin Cancer Res 24:1103-1113
Zhu, Haiyan; Gu, Xiang; Xia, Lu et al. (2018) A Novel TGF? Trap Blocks Chemotherapeutics-Induced TGF?1 Signaling and Enhances Their Anticancer Activity in Gynecologic Cancers. Clin Cancer Res 24:2780-2793
Bandyopadhyay, Abhik; Favours, Edward; Phelps, Doris A et al. (2018) Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models. Pediatr Blood Cancer 65:
Azpurua, Jorge; Mahoney, Rebekah E; Eaton, Benjamin A (2018) Transcriptomics of aged Drosophila motor neurons reveals a matrix metalloproteinase that impairs motor function. Aging Cell 17:

Showing the most recent 10 out of 989 publications